Re­cur­sion ac­quires two AI-based drug dis­cov­ery com­pa­nies in $87.5M deal

AI drug de­vel­op­er Re­cur­sion Phar­ma­ceu­ti­cals has brought two more AI-fo­cused com­pa­nies with their own dis­cov­ery plat­forms un­der its wing in an ac­qui­si­tion worth $87.5 mil­lion, the com­pa­ny an­nounced to­day.

Re­cur­sion is buy­ing both com­pa­nies, Cycli­ca and Va­lence, most­ly in eq­ui­ty. The deals come as in­sid­ers pre­dict a surge in biotech M&A — with small­er play­ers, not just Big Phar­ma, ready to jump on tuck-in ac­qui­si­tions of even small­er com­pa­nies.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER